← Leaderboards
Ursula Anne Matulonis
Dana-Farber Cancer Inst
$3,602,637
Attributed
$3,602,637
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.1M · FY2020–25$10M$7.5M$5M$2.5M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,987,805 · 9
By mechanism
P50$14,527,633 · 5
P01$6,294,219 · 2
P30$165,953 · 2
Top collaborators
- Alan David D'Andrea5 shared
- Cesar M Castro3 shared
- Panagiotis Konstantinopoulos2 shared
- Joyce Liu2 shared
- David R Spriggs2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Geoffrey I Shapiro$18,639,470
- Panagiotis Konstantinopoulos$4,290,380
- Joyce Liu$1,990,890
Others in their field
Other Emerging Leaders on “Grant”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$208,271,537
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
GrantCancer CenterMalignant Neoplasm Of OvaryResistanceClinical TrialsResearch PersonnelMalignant NeoplasmsProgramsResponseWomanOrganoidsFundingMucinousRelapseAdvocateCollaborationsTranslational ResearchLeadershipTumorRecurrenceSerousMutateBiological ModelsDiagnosis
Grant awards (23)
Targeting Replication Stress and DNA Damage Response in Uterine Cancer$2,955,234
P01 · FY2025 · CA · contact PI
Administrative Core$175,626
P01 · FY2025 · CA · contact PI
Program 02: Gynecologic Cancers$41,528
P30 · FY2025 · CA · contact PI
Targeting Replication Stress and DNA Damage Response in Uterine Cancer$2,971,802
P01 · FY2024 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,309,363
P50 · FY2024 · CA
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma$390,649
P50 · FY2024 · CA · contact PI
Administrative Core$191,557
P01 · FY2024 · CA · contact PI
Developmental Research Program (DRP)$168,022
P50 · FY2024 · CA · contact PI
Program 02: Gynecologic Cancers$40,515
P30 · FY2024 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,245,572
P50 · FY2023 · CA
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma$383,397
P50 · FY2023 · CA · contact PI
Developmental Research Program (DRP)$149,725
P50 · FY2023 · CA · contact PI
Program 02: Gynecologic Cancers$41,955
P30 · FY2023 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,156,021
P50 · FY2022 · CA
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma$541,179
P50 · FY2022 · CA · contact PI
Developmental Research Program (DRP)$294,401
P50 · FY2022 · CA · contact PI
Program 02: Gynecologic Cancers$41,955
P30 · FY2022 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,264,107
P50 · FY2021 · CA
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma$385,456
P50 · FY2021 · CA · contact PI
Developmental Research Program (DRP)$151,784
P50 · FY2021 · CA · contact PI
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant$2,483,069
P50 · FY2020 · CA
Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma$429,166
P50 · FY2020 · CA · contact PI
Developmental Research Program (DRP)$175,722
P50 · FY2020 · CA · contact PI